CA2451874C - Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par des cellules endotheliales - Google Patents

Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par des cellules endotheliales Download PDF

Info

Publication number
CA2451874C
CA2451874C CA2451874A CA2451874A CA2451874C CA 2451874 C CA2451874 C CA 2451874C CA 2451874 A CA2451874 A CA 2451874A CA 2451874 A CA2451874 A CA 2451874A CA 2451874 C CA2451874 C CA 2451874C
Authority
CA
Canada
Prior art keywords
ser
pro
gly
ala
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2451874A
Other languages
English (en)
French (fr)
Other versions
CA2451874A1 (fr
Inventor
Salman Al-Mahmood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENE SIGNAL INTERNATIONAL SA
Original Assignee
GENE SIGNAL INTERNATIONAL SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENE SIGNAL INTERNATIONAL SA filed Critical GENE SIGNAL INTERNATIONAL SA
Publication of CA2451874A1 publication Critical patent/CA2451874A1/fr
Application granted granted Critical
Publication of CA2451874C publication Critical patent/CA2451874C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
CA2451874A 2001-06-14 2002-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par des cellules endotheliales Expired - Fee Related CA2451874C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0107805 2001-06-14
FR0107805A FR2826010B1 (fr) 2001-06-14 2001-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par les cellules endotheliales
PCT/FR2002/002067 WO2002103014A2 (fr) 2001-06-14 2002-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires

Publications (2)

Publication Number Publication Date
CA2451874A1 CA2451874A1 (fr) 2002-12-27
CA2451874C true CA2451874C (fr) 2013-07-30

Family

ID=8864317

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2451874A Expired - Fee Related CA2451874C (fr) 2001-06-14 2002-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par des cellules endotheliales

Country Status (13)

Country Link
US (3) US7417033B2 (enExample)
EP (2) EP2166095A3 (enExample)
JP (1) JP4153421B2 (enExample)
AT (1) ATE435911T1 (enExample)
AU (1) AU2002345669B9 (enExample)
CA (1) CA2451874C (enExample)
CY (1) CY1109464T1 (enExample)
DE (1) DE60232883D1 (enExample)
DK (1) DK1409672T3 (enExample)
ES (1) ES2331835T3 (enExample)
FR (1) FR2826010B1 (enExample)
PT (1) PT1409672E (enExample)
WO (1) WO2002103014A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031277A2 (en) * 2005-09-14 2007-03-22 Medizinische Universität Wien Means and methods for diagnosing endometriosis
US8032556B1 (en) * 2008-03-07 2011-10-04 Symantec Corporation Systems and methods for user profile data delivery
US8470997B2 (en) 2009-02-05 2013-06-25 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US8580947B2 (en) 2009-02-05 2013-11-12 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
EP2418279A1 (en) * 2010-08-10 2012-02-15 Gene Signal International SA Injectable pharmaceutical composition for preventing, stabilising and/or inhibiting pathological neovascularization-related conditions
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
EP2540828A1 (en) 2011-06-30 2013-01-02 Gene Signal International SA Composition comprising inhibitors of IRS-1 and of VEGF
CA2840143A1 (en) 2011-06-30 2013-01-03 Gene Signal International Sa Composition comprising inhibitors of irs-1 and of vegf
US9359604B2 (en) 2012-07-03 2016-06-07 Gene Signal International Sa Inhibitor of IRS-1 for treating skin disorders
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
CN122055446A (zh) * 2024-06-26 2026-05-15 思合基因(北京)生物科技有限公司 一种靶向IRS-1 mRNA的寡聚核苷酸及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013083A1 (en) * 1991-01-18 1992-08-06 Joslin Diabetes Center, Inc. Nucleic acid encoding insulin receptor substrate-1 (irs-1), irs-1 protein, diseases, therapy associated with the metabolism of irs-1
FR2733913B1 (fr) * 1995-05-09 1997-08-01 Sanofi Sa Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant
US6498139B1 (en) * 1997-09-29 2002-12-24 Daiichi Pharmaceutical Co., Ltd. Remedies for diseases caused by insulin resistance
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000070070A1 (en) * 1999-05-18 2000-11-23 Dnavec Research Inc. Paramyxoviridae virus vector defective in envelope gene

Also Published As

Publication number Publication date
AU2002345669B9 (en) 2006-06-29
US8828959B2 (en) 2014-09-09
EP1409672B1 (fr) 2009-07-08
US20090082292A1 (en) 2009-03-26
WO2002103014A3 (fr) 2004-02-26
JP2004538272A (ja) 2004-12-24
EP2166095A2 (fr) 2010-03-24
US7417033B2 (en) 2008-08-26
FR2826010A1 (fr) 2002-12-20
ATE435911T1 (de) 2009-07-15
FR2826010B1 (fr) 2005-02-25
US20040162257A1 (en) 2004-08-19
US20080293658A1 (en) 2008-11-27
AU2002345669B2 (en) 2006-02-02
DK1409672T3 (da) 2009-11-09
CY1109464T1 (el) 2014-08-13
US7855184B2 (en) 2010-12-21
EP2166095A3 (fr) 2012-01-04
CA2451874A1 (fr) 2002-12-27
EP1409672A2 (fr) 2004-04-21
WO2002103014A2 (fr) 2002-12-27
DE60232883D1 (de) 2009-08-20
ES2331835T3 (es) 2010-01-18
PT1409672E (pt) 2009-11-04
JP4153421B2 (ja) 2008-09-24

Similar Documents

Publication Publication Date Title
JP4255123B2 (ja) 転写dna結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド(cdodn)
US8828959B2 (en) Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells
EP0581848B1 (fr) Oligonucleotides fermes, antisens et sens, et leurs applications
WO2013163455A2 (en) A drug screening platform for rett syndrome
FR2553420A1 (fr) Nouveaux oligodesoxynucleotides et polydesoxynucleotides utiles comme agents antiviraux
JP2005512976A (ja) Rna干渉により線維化疾患を処置するための医薬
EP2925882B1 (fr) Méthode de criblage à haut-débit pour l'identification de biomarqueurs, cibles thérapeutiques ou d'agents thérapeutiques
EP3247716A2 (en) Mir-92 inhibitors and uses thereof
Ma et al. Dual anti-angiogenic and anti-inflammatory action of tRNA-Cys-5-0007 in ocular vascular disease
JP2009518022A (ja) 抗ミオシンVasiRNAおよび皮膚の脱色
EP0707644B1 (fr) Utilisation de compositions pharmaceutiques pour le traitement des maladies neurodegeneratives
JP5522435B2 (ja) Mxd3遺伝子の発現阻害による肥満の抑制
CA2322055C (fr) Nouvelle famille de canaux potassium de mammiferes mecanosensibles et actives par les acides gras polyinsatures et leur utilisation notamment pour le criblage de drogues
EP0722496B1 (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives
WO1996035791A1 (fr) Sequence d'adn codant pour un ribozyme a titre de medicament, et compositions pharmaceutiques la contenant
JPWO2004026343A1 (ja) 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
JP4316661B2 (ja) 転写dna結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド(cdodn)
JP2009142295A (ja) 転写dna結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド(cdodn)
CA3207034A1 (fr) Oligonucleotides anti-sens pour leur utilisation dans un traitement anticancereux
FR2708283A1 (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831